Ronald Klein1, Kristine E Lee, Ronald E Gangnon, Barbara E K Klein. 1. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726-2336, USA. kleinr@epi.ophth.wisc.edu
Abstract
PURPOSE: To describe visual impairment (VI) over a 20-year period and its associations with age-related eye diseases and socioeconomic factors in the Beaver Dam Eye Study. DESIGN: Population-based cohort study. PARTICIPANTS: Four thousand nine hundred twenty-six persons 43 to 86 years of age participated in the baseline examination phase from 1988 through 1990, and 3721, 2962, 2375, and 1913 persons participated in follow-up examinations each spaced 5 years apart from 1993 through 1995, 1998 through 2000, 2003 through 2005, and 2008 through 2010, respectively. METHODS: Best-corrected visual acuity after refraction, assessed by the Early Treatment Diabetic Retinopathy Study protocol. MAIN OUTCOME MEASURES: Incidence of VI, defined as best-corrected visual acuity of poorer than 20/40 in the better eye in persons with one or both eyes 20/40 or better at the beginning of a 5-year interval, and incidence of severe VI, defined as best-corrected visual acuity of 20/200 or worse in the better eye in persons with one or both eyes better than 20/200 at the beginning of a 5-year interval. RESULTS: Overall incidence of VI between examinations (5-year interval) was 1.4% (varying from 0.1% in persons 50-54 years of age to 14.6% in those 85 years of age and older), whereas for severe VI it was 0.4% (varying from 0.0% in persons 50-54 years of age to 6.9% in those ≥ 85 years of age). The incidence of VI decreased for each (2003-2005 to 2008-2010; odds ratio fourth interval vs. first interval, 0.53; 95% confidence interval, 0.32-0.87; P = 0.01 period after adjustment for age, from the first 5-year interval between examinations (1988-1990 to 1993-1995) to the fourth and most recent 5-year interval ). This period effect was no longer significant after adjustment for age-related macular degeneration. Age-related macular degeneration remained the leading cause of incident severe VI (54% of eyes with incident severe VI, which was as low as 40% and as high as 57% for specific visits), with no evidence of a trend across visits. The overall frequency of VI correctable with new refraction was 38% of all eyes with VI. CONCLUSIONS: These data provide population-based estimates that show a high (15%) 5-year incidence of VI in persons 85 years of age and older. Age-related macular degeneration remained the leading cause of severe VI in this population over the 20 years of the study. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
PURPOSE: To describe visual impairment (VI) over a 20-year period and its associations with age-related eye diseases and socioeconomic factors in the Beaver Dam Eye Study. DESIGN: Population-based cohort study. PARTICIPANTS: Four thousand nine hundred twenty-six persons 43 to 86 years of age participated in the baseline examination phase from 1988 through 1990, and 3721, 2962, 2375, and 1913 persons participated in follow-up examinations each spaced 5 years apart from 1993 through 1995, 1998 through 2000, 2003 through 2005, and 2008 through 2010, respectively. METHODS: Best-corrected visual acuity after refraction, assessed by the Early Treatment Diabetic Retinopathy Study protocol. MAIN OUTCOME MEASURES: Incidence of VI, defined as best-corrected visual acuity of poorer than 20/40 in the better eye in persons with one or both eyes 20/40 or better at the beginning of a 5-year interval, and incidence of severe VI, defined as best-corrected visual acuity of 20/200 or worse in the better eye in persons with one or both eyes better than 20/200 at the beginning of a 5-year interval. RESULTS: Overall incidence of VI between examinations (5-year interval) was 1.4% (varying from 0.1% in persons 50-54 years of age to 14.6% in those 85 years of age and older), whereas for severe VI it was 0.4% (varying from 0.0% in persons 50-54 years of age to 6.9% in those ≥ 85 years of age). The incidence of VI decreased for each (2003-2005 to 2008-2010; odds ratio fourth interval vs. first interval, 0.53; 95% confidence interval, 0.32-0.87; P = 0.01 period after adjustment for age, from the first 5-year interval between examinations (1988-1990 to 1993-1995) to the fourth and most recent 5-year interval ). This period effect was no longer significant after adjustment for age-related macular degeneration. Age-related macular degeneration remained the leading cause of incident severe VI (54% of eyes with incident severe VI, which was as low as 40% and as high as 57% for specific visits), with no evidence of a trend across visits. The overall frequency of VI correctable with new refraction was 38% of all eyes with VI. CONCLUSIONS: These data provide population-based estimates that show a high (15%) 5-year incidence of VI in persons 85 years of age and older. Age-related macular degeneration remained the leading cause of severe VI in this population over the 20 years of the study. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Authors: Nathan Congdon; Benita O'Colmain; Caroline C W Klaver; Ronald Klein; Beatriz Muñoz; David S Friedman; John Kempen; Hugh R Taylor; Paul Mitchell Journal: Arch Ophthalmol Date: 2004-04
Authors: Ronald Klein; Kristine E Lee; Michael Y Tsai; Karen J Cruickshanks; Ronald E Gangnon; Barbara E K Klein Journal: Ophthalmology Date: 2018-12-17 Impact factor: 12.079
Authors: Chelsea E Myers; Barbara E K Klein; Ronald Gangnon; Theru A Sivakumaran; Sudha K Iyengar; Ronald Klein Journal: Ophthalmology Date: 2014-06-20 Impact factor: 12.079
Authors: Geoffrey K Broadhead; Thomas Hong; John R Grigg; Peter McCluskey; Timothy E Schlub; Kimberly Spooner; Andrew A Chang Journal: Int Ophthalmol Date: 2020-07-14 Impact factor: 2.031
Authors: Barbara E K Klein; Kerri P Howard; Sudha K Iyengar; Theru A Sivakumaran; Kristin J Meyers; Karen J Cruickshanks; Ronald Klein Journal: Invest Ophthalmol Vis Sci Date: 2014-08-14 Impact factor: 4.799
Authors: Sharon L Christ; D Diane Zheng; Bonnielin K Swenor; Byron L Lam; Sheila K West; Stacey L Tannenbaum; Beatriz E Muñoz; David J Lee Journal: JAMA Ophthalmol Date: 2014-12 Impact factor: 7.389
Authors: Ronald E Gangnon; Kristine E Lee; Barbara E K Klein; Sudha K Iyengar; Theru A Sivakumaran; Ronald Klein Journal: Invest Ophthalmol Vis Sci Date: 2014-03-20 Impact factor: 4.799
Authors: Ronald Klein; Stacy M Meuer; Chelsea E Myers; Gabriëlle H S Buitendijk; Elena Rochtchina; Farzana Choudhury; Paulus T V M de Jong; Roberta McKean-Cowdin; Sudha K Iyengar; Xiaoyi Gao; Kristine E Lee; Johannes R Vingerling; Paul Mitchell; Caroline C W Klaver; Jie Jin Wang; Barbara E K Klein Journal: Ophthalmic Epidemiol Date: 2014-02 Impact factor: 1.648